Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

• Váldodahkkit: Peter P. Toth (Dahkki), Gregory G. Schwartz (Dahkki), Stephen J. Nicholls (Dahkki), Aziz Khan (Dahkki), Michael Szarek (Dahkki), Henry N. Ginsberg (Dahkki), Jan O. Johansson (Dahkki), Kamyar Kalantar-Zadeh (Dahkki), Ewelina Kulikowski (Dahkki), Ken Lebioda (Dahkki), Norman C.W. Wong (Dahkki), Michael Sweeney (Dahkki), Kausik K. Ray (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Elsevier, 2022-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background: Nonalcoholic fatty liver disease (NAFLD) is common among patients with type 2 diabetes mellitus (T2DM) and is associated with increased risk for coronary atherosclerosis and acute cardiovascular (CV) events. We employed the validated, non-invasive Angulo NAFLD fibrosis score (FS) in an i...